Braveheart Bio (BRVE) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma is the larger company by market cap ($1.83 billion vs $1.75 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRVE | URGN |
|---|---|---|
| Share price | $19.39 | $37.47 |
| Market cap | $1.75B | $1.83B |
| 1-day change | +1.55% | +1.31% |
| YTD return | — | +57.90% |
| 1-year return | — | +113.39% |
| 5-year return | — | +117.27% |
| Forward P/E | — | 13.41 |
| EPS (TTM) | $-6.08 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $32.00 | $50.81 |
| 52-week low | $17.86 | $15.86 |
| Distance from 52-week high | -39.42% | -26.26% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +133.43% | +60.15% |
| Average volume | 558.38K | 849.01K |
| Shares outstanding | 90.04M | 48.88M |
| Employees | 49 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Braveheart Bio
BRVE stock →Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
BRVE vs URGN FAQ
Which is bigger, Braveheart Bio or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.83B compared with $1.75B for Braveheart Bio (BRVE).
Are Braveheart Bio and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.